ABEONA THERAPEUTICS INC. Increase Decrease In Operating Lease Liability
ABEONA THERAPEUTICS INC. (ABEO) reported Increase Decrease In Operating Lease Liability of -$384.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-08-13
- ABEONA THERAPEUTICS INC. increase decrease in operating lease liability for the quarter ending 2026-06-30 was -$202.00K.
- ABEONA THERAPEUTICS INC. increase decrease in operating lease liability for the quarter ending 2026-03-31 was -$182.00K.
- ABEONA THERAPEUTICS INC. increase decrease in operating lease liability for the quarter ending 2025-12-31 was $472.00K.
- ABEONA THERAPEUTICS INC. increase decrease in operating lease liability for the quarter ending 2025-09-30 was -$381.00K.
- ABEONA THERAPEUTICS INC. increase decrease in operating lease liability for fiscal 2025 was -$576.00K.
- ABEONA THERAPEUTICS INC. increase decrease in operating lease liability for fiscal 2024 was -$1.31M.
- ABEONA THERAPEUTICS INC. increase decrease in operating lease liability for fiscal 2023 was -$1.20M.
- ABEONA THERAPEUTICS INC. increase decrease in operating lease liability for fiscal 2022 was -$1.38M.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$202.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$384.00K 10-Q · filed 2026-08-13 | $88.00K derived: sum of 3 quarters · filed 2026-08-13 | -$293.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$182.00K 10-Q · filed 2026-05-13 | $290.00K derived: sum of 2 quarters · filed 2026-05-13 | -$91.00K derived: sum of 3 quarters · filed 2026-05-13 | -$396.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $472.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $91.00K derived: sum of 2 quarters · filed 2026-03-17 | -$214.00K derived: sum of 3 quarters · filed 2026-08-13 | -$576.00K 10-K · filed 2026-03-17 |
| 2025-09-30 | -$381.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$686.00K derived: sum of 2 quarters · filed 2026-08-13 | -$1.05M 10-Q · filed 2025-11-12 | -$1.42M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$305.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$667.00K 10-Q · filed 2026-08-13 | -$1.04M derived: sum of 3 quarters · filed 2026-08-13 | -$1.39M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$362.00K 10-Q · filed 2026-05-13 | -$736.00K derived: sum of 2 quarters · filed 2026-05-13 | -$1.09M derived: sum of 3 quarters · filed 2026-05-13 | -$1.37M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | -$374.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | -$725.00K derived: sum of 2 quarters · filed 2026-03-17 | -$1.00M derived: sum of 3 quarters · filed 2026-03-17 | -$1.31M 10-K · filed 2026-03-17 |
| 2024-09-30 | -$351.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$631.00K derived: sum of 2 quarters · filed 2025-11-12 | -$941.00K 10-Q · filed 2025-11-12 | -$1.23M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$280.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$590.00K 10-Q · filed 2025-08-14 | -$882.00K derived: sum of 3 quarters · filed 2025-08-14 | -$1.16M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | -$310.00K 10-Q · filed 2025-05-15 | -$602.00K derived: sum of 2 quarters · filed 2025-05-15 | -$884.00K derived: sum of 3 quarters · filed 2025-05-15 | -$1.20M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | -$292.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | -$574.00K derived: sum of 2 quarters · filed 2025-03-20 | -$888.00K derived: sum of 3 quarters · filed 2025-03-20 | -$1.20M 10-K · filed 2025-03-20 |
| 2023-09-30 | -$282.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$596.00K derived: sum of 2 quarters · filed 2024-11-14 | -$904.00K 10-Q · filed 2024-11-14 | |
| 2023-06-30 | -$314.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | -$622.00K 10-Q · filed 2024-08-12 | ||
| 2023-03-31 | -$308.00K 10-Q · filed 2024-05-15 | |||
| 2022-12-31 | -$1.38M 10-K · filed 2024-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |